Early detection of cancer relapse after prostatectomy using very sensitive prostate-specific antigen measurements

British Journal of Urology

Volumn 79, Issue SUPPL. 1, 1997, Pages 82-86

  Witherspoon, L R ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER RECURRENCE; CONFERENCE PAPER; HUMAN; IMMUNOASSAY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

AGE FACTORS; AGED; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0031401512     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.1997.tb00806.x     Document Type: Article

References (25)

1. Hara M, Inorre T, Fukuyama T. Some physico-chemical characteristics of gamma-seminoprotein. an antigenic component specific for human seminal plasma. Jap J Legal Med 1971: 25: 322-6
2. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358-68
3. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991: 145: 907-23
4. Ploch NR. Brawer MK. How to use prostate-specific antigen. Urology 1994: 43 (Suppl. 2): 27-35
5. Lange PH. Ercole CJ, Lightner DJ. Fraley EE. Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989: 141: 873-9
6. Armbruster DA. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993; 39: 181-95
7. Wang MC, Valenzuela LA. Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979: 17: 159-63
8. Seamonds B, Yang N. Anderson K. Whitaker B, Shaw LM. Bollinger JR. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Vrology 1986: 6: 472-9
9. Killian CS, Yang N. Emrich LJ et al and the Investigators of the National Prostatic Cancer Project. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985: 45: 886-91
10. Myrtle JF. Ivor LP. Measurement of prostate-specific antigen (PSA) in serum by a two-site immunometric method (Hybritech Tandem-RJTandem-E PSA). In Catalona WJ, Coffey DS. Karr JP, eds. Clinical Aspects of Prostate Cancer. New York: Elsevier Science Publishing, 1989: 161-71
11. Diamandis EP, Yu H. Melegos DN. Ultrasensitive prostate-specific antigen assays and their clinical application. Clin Chem 1996; 42: 853-7
12. Stamey TM. Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate-specific antigen assays mislead clinicians. Clin Chem 1996: 42: 849-52
13. Graves HCB. Wehner N, Stamey TA. Ultrasensitive radio-immunoassay of prostate-specific antigen. Clin Chem 1992; 38: 735-42
14. Liedtke RJ. Kroon G. Batjer JD. Modified assay of prostate-specific antigen with a detection limit <0.1 mgJL. Clin Chem 1993; 39: 2150-4
15. Yu H. Diamandis EP. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 1993; 39: 2108-14
16. Vieira JGH. Nishida SK, Pereira AB. Arraes RE, Verreschi ITN. Serum levels of prostate-specific antigen in normal boys throughout puberty. J Clin Endocrinol Metab 1994; 78: 1185-7
17. 1-anti-chymotrypsin. Clin Chem 1993; 39: 2098-103
18. Klee GG, Preissner CM, Oesterling JE. Development of a highly sensitive immunochemiluminometric assay for prostate-specific antigen. Urology 1994: 44: 76-82
19. Diamandis EP. New diagnostic applications of prostate specific antigen. Br J Urol 1997; 79: 87-91
20. Yu H, Diamandis EP. Measurement of serum prostate specific antigen levels in women and in prostatectomised men with an ultrasensitive immunoassay technique. J Urol 1995; 153: 1004-8
21. Witherspoon LR, Babson AL, Oison DR. IMMULITE chemiluminescent immunoassay system. In Chan DW, ed, Immunoassay Automation: An Updated Guide to Systems. San Diego, CA: Academic Press, 1996: 103-30
22. Babson AL, Oison DR, Palmieri T, Ross AF, Becker DM, Mulqueen PJ. The IMMULITE® assay tube: a new approach to heterogeneous ligand assay. Clin Chem 1991; 37: 1521-2
23. Blankenstein MA, van Zon J. Recognition of free prostate specific antigen (PSA) and PSA-ACT complex by different assays. Anticancer Res 1995; 15: 6A, Abstr 68
24. Witherspoon LR, Lapeyrolerie T. Very sensitive PSA measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within two years after radical prostatectomy. J Urol 1997; 157; in press
25. L.R. Witherspoon, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, LA 70121, USA.